What is the history of Lennox-Gastaut syndrome?

Lennox-Gastaut syndrome (LGS) was formally characterized in the 1960s by French neurologists who identified a specific triad of clinical symptoms, cognitive impairment, and a distinct electroencephalogram (EEG) pattern. Since its initial description, our understanding of Lennox-Gastaut syndrome has evolved from viewing it as a monolithic diagnosis to recognizing it as a complex, heterogeneous developmental and epileptic encephalopathy with diverse underlying genetic and structural causes.

Who first identified and described Lennox-Gastaut syndrome?

While various forms of childhood epilepsy were documented in the early 20th century, the condition we now recognize as Lennox-Gastaut syndrome was defined in the mid-1960s. The syndrome is named after William G. Lennox, an American neurologist who pioneered the study of childhood seizures, and Henri Gastaut, a French neurologist who further refined the clinical criteria. In 1966, Gastaut and his colleagues published a definitive description of the syndrome, highlighting the characteristic "slow spike-and-wave" pattern on an EEG, which remains a diagnostic cornerstone of Lennox-Gastaut syndrome to this day.

How has our understanding of the condition evolved?

Historically, medicine struggled to categorize the various forms of severe childhood epilepsy. Before the formal naming of Lennox-Gastaut syndrome, many children were simply diagnosed with "idiopathic" or "symptomatic" epilepsy without a clear understanding of the underlying pathophysiology. Over the decades, researchers moved away from viewing it as a single disease entity toward understanding it as a "final common pathway" resulting from various insults to the developing brain, including genetic mutations, structural brain malformations, and prenatal infections.

What are the major milestones in the treatment of Lennox-Gastaut syndrome?

Treatment for Lennox-Gastaut syndrome has progressed from limited supportive care to targeted, multi-modal therapies. Historically, management relied almost exclusively on older anti-seizure medications that often had significant side effects. The following milestones represent key shifts in the therapeutic landscape:

• 1980s-1990s: The introduction of newer anti-epileptic drugs (AEDs) provided more options for seizure control.


• 1990s: The adoption of the ketogenic diet and the development of the vagus nerve stimulator (VNS) offered non-pharmacological alternatives for drug-resistant cases.


• 2010s-Present: The FDA approval of targeted therapies, such as cannabidiol and clobazam specifically for Lennox-Gastaut syndrome, marked a new era of precision medicine.


• Modern Era: The use of corpus callosotomy and other surgical interventions has provided significant relief for specific seizure types like drop attacks.

How have modern genetics and technology changed the landscape?

Modern genetic sequencing, including whole-exome and whole-genome testing, has revolutionized the diagnosis of Lennox-Gastaut syndrome. We now know that many cases are caused by pathogenic variants in genes such as SCN1A, GABRB3, and CDKL5. This genetic revolution has helped move the community away from historical misconceptions—such as the idea that the condition was solely caused by birth trauma or parental factors—toward a model of molecular diagnosis. Today, 105 members of the DiseaseMaps.org community are actively sharing their experiences, helping to bridge the gap between clinical data and the lived reality of families navigating this complex diagnosis.

Next steps

• Consult with a board-certified epileptologist or pediatric neurologist who specializes in complex developmental encephalopathies.


• Consider genetic counseling to discuss whether current testing can identify an underlying genetic cause for your family member.


• Join the DiseaseMaps.org community to connect with other families and share experiences regarding care management.


• Review the latest clinical trials on clinicaltrials.gov to see if your loved one may be a candidate for emerging therapies.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Lennox-Gastaut Syndrome.


• Orphanet: Rare Disease Database (ORPHA:507).


• Online Mendelian Inheritance in Man (OMIM): #605960.


• Lennox-Gastaut Syndrome Foundation: Educational Resources.